Cargando…
Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
[Image: see text] WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells. We report the discovery and optimization of a 3,4,5-trisubstituted pyridine 9 using a high-throughput cell-based reporte...
Autores principales: | Mallinger, Aurélie, Crumpler, Simon, Pichowicz, Mark, Waalboer, Dennis, Stubbs, Mark, Adeniji-Popoola, Olajumoke, Wood, Bozena, Smith, Elizabeth, Thai, Ching, Henley, Alan T., Georgi, Katrin, Court, William, Hobbs, Steve, Box, Gary, Ortiz-Ruiz, Maria-Jesus, Valenti, Melanie, De Haven Brandon, Alexis, TePoele, Robert, Leuthner, Birgitta, Workman, Paul, Aherne, Wynne, Poeschke, Oliver, Dale, Trevor, Wienke, Dirk, Esdar, Christina, Rohdich, Felix, Raynaud, Florence, Clarke, Paul A., Eccles, Suzanne A., Stieber, Frank, Schiemann, Kai, Blagg, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2015
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767141/ https://www.ncbi.nlm.nih.gov/pubmed/25680029 http://dx.doi.org/10.1021/jm501436m |
Ejemplares similares
-
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
por: Dale, Trevor, et al.
Publicado: (2015) -
Discovery of Potent,
Selective, and Orally Bioavailable
Small-Molecule Modulators of the Mediator Complex-Associated Kinases
CDK8 and CDK19
por: Mallinger, Aurélie, et al.
Publicado: (2016) -
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases
por: Clarke, Paul A, et al.
Publicado: (2016) -
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with
Potent, Selective Affinity for CDK8/19
por: Mallinger, Aurélie, et al.
Publicado: (2016) -
Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a
Dual FLT3/Aurora
Kinase Inhibitor as an Orally Bioavailable Preclinical Development
Candidate for the Treatment of Acute Myeloid Leukemia
por: Bavetsias, Vassilios, et al.
Publicado: (2012)